دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Dermatologic Care for Displaced Persons—Key Considerations and Approaches
Soo Hyun Choi, BA1; Karolyn A. Wanat, MD2; Alexia Knapp, MD3,4
doi : 10.1001/jamadermatol.2022.6375
April 2023, Vol 159, No. 4, Pages 364-463
Incorporating Social Determinants of Health Into Medical Decision-making—Implications for Dermatology
Kaushik P. Venkatesh, MBA, MPH1,2; Balaji Jothishankar, MD, MBA1,2; Vinod E. Nambudiri, MD, MBA, EdM1,2
Characterizing Epidemiology and Burden of Disease in Alopecia Areata—Making It Count
Amy J. McMichael, MD1; Mya L. Roberson, MSPH, PhD2
Reaffirmed USPSTF Recommendation Against Serologic Screening for Genital HerpesEmpowering Clinicians and Reducing Potential Harm
Howa Yeung, MD, MSc1,2,3; Anandi N. Sheth, MD, MSc3,4; Lauren F. Collins, MD, MSc3,4
Long-term Outcomes After Rituximab Treatment for Patients With Systemic SclerosisFollow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels
Ai Kuzumi, MD, PhD1; Satoshi Ebata, MD, PhD1; Takemichi Fukasawa, MD, PhD1; Kazuki M. Matsuda, MD1; Hirohito Kotani, MD1; Asako Yoshizaki-Ogawa, MD, PhD1; Shinichi Sato, MD, PhD1; Ayumi Yoshizaki, MD, PhD1
doi : 10.1001/jamadermatol.2022.6340
Importance Rituximab is emerging as a promising therapeutic option for systemic sclerosis (SSc), but its long-term outcomes and response markers are unknown.
Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisA Systematic Review and Meta-analysis
Erika Yue Lee, MD1,2; Christopher Knox, BSc3; Elizabeth Jane Phillips, MD4,5,6,7
doi : 10.1001/jamadermatol.2022.6378
Importance Antibiotics are an important risk for Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), which are the most severe types of drug hypersensitivity reaction with a mortality rate up to 50%. To our knowledge, no global systematic review has described antibiotic-associated SJS/TEN.
Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease
Emily Baumrin, MD1; Laura X. Baker, MD2; Michael Byrne, MD3; Paul J. Martin, MD4,5; Mary E. Flowers, MD4,5; Lynn Onstad, ScM4; Najla El Jurdi, MD6; Heidi Chen, PhD7; Alicia Beeghly-Fadiel, MPH, PhD3; Stephanie J. Lee, MD, MPH4,5; Eric R. Tkaczyk, MD, PhD8,9
doi : 10.1001/jamadermatol.2022.6624
Importance Prior studies have demonstrated an association between cutaneous chronic graft-vs-host disease (cGVHD) and mortality. Assessment of the prognostic value of different measures of disease severity would assist in risk stratification.
Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or UniversalisA 2-Step Double-Blind Randomized Clinical Trial
Pascal Joly, MD, PhD1; Audrey Lafon, MD1; Estelle Houivet, MS2; Nathalie Donnadieu, MD3; Marie-Aleth Richard, MD, PhD4; Alain Dupuy, MD, PhD5; Emmanuel Delaporte, MD, PhD6; Philippe Bernard, MD, PhD7; Laurent Machet, MD, PhD8; Antonella Tosti, MD, PhD9; Veronique Del Marmol, MD, PhD10; Ramon Grimalt, MD, PhD11; Pierre A. de Viragh, MD, PhD12; Jacques Benichou, MD, PhD3; Olivier Chosidow, MD, PhD13; Philippe Assouly, MD14; Pascal Reygagne, MD14
doi : 10.1001/jamadermatol.2022.6687
Importance Poor therapeutic results have been reported in patients with alopecia areata totalis (AT) or universalis (AU), the most severe and disabling types of alopecia areata (AA). Methotrexate, an inexpensive treatment, might be effective in AU and AT.
Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population
Arash Mostaghimi, MD, MPA, MPH1; Wei Gao, MS, PhD2; Markqayne Ray, PharmD, MBA3; Lauren Bartolome, PharmD, MS4; Travis Wang, MD, MS2; Christopher Carley, BA2; Nicolae Done, PhD2; Elyse Swallow, MA2
doi : 0.1001/jamadermatol.2023.0002
Importance Alopecia areata (AA) is characterized by nonscarring hair loss of the scalp, face, and/or body. Alopecia totalis (AT) and alopecia universalis (AU) involve complete loss of the scalp and body hair, respectively. The epidemiology of AA in the US remains unclear, having previously been extrapolated from older studies that were limited to specific geographic areas or clinical settings, or from self-reported data.
Overall and Racial and Ethnic Subgroup Prevalences of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Nene Sy, BS1; Nicole Mastacouris, BS1; Andrew Strunk, MA1; Amit Garg, MD1,2
doi : 10.1001/jamadermatol.2023.0016
Importance Prevalences of alopecia areata (AA), alopecia totalis (AT), and alopecia universalis (AU) are poorly established.
Mpox—A Rapidly Evolving Disease
Edward W. Cowen, MD, MHSc1; Eric R. Tkaczyk, MD, PhD2,3; Scott A. Norton, MD, MPH, MSc4; Kieron S. Leslie, MBBS, DTM&H5
doi : 10.1001/jamadermatol.2023.0041
The 2022 mpox outbreak has rapidly emerged onto the global medical scene while the world continues to grapple with the COVID-19 pandemic. Unlike COVID-19, however, most patients with mpox present with skin findings, the evolving clinical presentation of which may be mistaken for other common skin diseases, particularly sexually transmitted infections.
Strategies to Improve Adherence to Skin Self-examination and Other Self-management Practices in People at High Risk of MelanomaA Scoping Review of Randomized Clinical Trials
Deonna M. Ackermann, MPH1; Karen Bracken, PhD2; Monika Janda, PhD3; Robin M. Turner, PhD4; Jolyn K. Hersch, PhD1; Dorothy Drabarek, MIPH1; Katy J. L. Bell, PhD1
Surgical Procedural Definitions for Hidradenitis Suppurativa Developed by Expert Delphi Consensus
Helen Bui, MD1; Falk G. Bechara, MD2; Ralph George, MD3; Stephanie Goldberg, MD4; Iltefat Hamzavi, MD5; Joslyn S. Kirby, MD, MEd, MS6; Drew Saylor, MD7; Christopher J. Sayed, MD1,8
doi : 10.1001/jamadermatol.2022.6266
rtance Various surgical approaches for hidradenitis suppurativa (HS) have been described in the literature, but the nomenclature is inconsistent. Excisions have been described as wide, local, radical, and regional with variable descriptions of margins.
Linear and Annular Lupus Panniculitis of the Scalp
Tian Chen, MD1; Dong-Lai Ma, MD, PhD1
Eruptive Xanthomas
Ke-yun Tang, MD1; Meng-yin Wu, MD1; Jun Li, MD1
Numerous Ulcerated Plaques of the Trunk and Extremities in a Patient Receiving Long-term Hydroxyurea Therapy
Paul Wirth, MD1; Todd V. Cartee, MD2; Charlene Lam, MD2
Long History of Multiple Painless Scalp Nodules in a Middle-aged Woman
Yue-hua Li, MD1; Cheng-jiang Wei, MD, PhD1; Zhi-chao Wang, MD, MPH1
Trends in the Prevalence of Eczema Among US Children by Age, Sex, Race, and Ethnicity From 1997 to 2018
Siri Choragudi, BS1; Gil Yosipovitch, MD1
Patient Perspectives on Clinic Note Transparency Within Dermatology
Kevin Yang, BS1,2; Charles B. Lau, BA2,3; William C. Lau, BA2,4; Vinod E. Nambudiri, MD, MBA, EdM2,5; Alice J. Watson, MD, MPH2,5
Treatment of Porokeratosis Ptychotropica With a Topical Combination of Cholesterol and Simvastatin
Marta Albanell-Fernández, PharmD1; Mar Luque-Luna, MD2; Carmen López-Cabezas, PharmD1; Francesc Alamon-Reig, MD2; Natalia Espinosa-Villaseñor, MD2; Lorena Barboza-Guadagnini, MD2; José M. Mascaró Jr, MD2,3
Vascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis
Suzanne Xu, BS1; Robert J. Patrignelli, MD2; Sarika Ramachandran, MD1; Fotios Koumpouras, MD3; Deborah Desir, MD3; Christine J. Ko, MD1,4; Jeff R. Gehlhausen, MD, PhD1
Shared Decision-making, Therapeutic Choice, and Decisional Regret in Alopecia Areata—Where Narrative Ethics Meets the Unconscious Bias of Clinicians
Leila Asfour, MBChB, BSc1; Bhaskar Narayan, MA, MB BChir2,3
Shared Decision-making, Therapeutic Choice and Decisional Regret in Alopecia Areata—Where Narrative Ethics Meets the Unconscious Bias of Clinicians—Reply
Kathie Huang, MD1,2; Arash Mostaghimi, MD, MPH, MPA1,2
